Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Medtronic
Johnson and Johnson
Colorcon

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXUBERA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Exubera

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00134147 A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control Completed Sanofi Phase 3 2005-04-01 To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
NCT00134147 A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control Completed Pfizer Phase 3 2005-04-01 To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
NCT00136916 Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes Terminated Pfizer Phase 3 2002-06-01 This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®. This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
NCT00137046 Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes Terminated Pfizer Phase 3 2002-05-01 This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus. The drug is called EXUBERA (inhaled insulin). This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.
NCT00138671 A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD Terminated Pfizer Phase 3 2003-01-01 A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
NCT00139659 A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma Completed Pfizer Phase 3 2003-01-01 A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
NCT00143247 Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Terminated Pfizer Phase 2 2003-03-01 This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exubera

Condition Name

Condition Name for Exubera
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 9
Diabetes Mellitus, Type 1 4
Diabetes Mellitus Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exubera
Intervention Trials
Diabetes Mellitus 25
Diabetes Mellitus, Type 2 11
Diabetes Mellitus, Type 1 5
Respiratory Aspiration 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exubera

Trials by Country

Trials by Country for Exubera
Location Trials
United States 356
Canada 56
United Kingdom 34
Spain 23
Brazil 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exubera
Location Trials
Florida 15
California 15
New York 14
Texas 14
Connecticut 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exubera

Clinical Trial Phase

Clinical Trial Phase for Exubera
Clinical Trial Phase Trials
Phase 4 7
Phase 3 15
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exubera
Clinical Trial Phase Trials
Completed 14
Terminated 10
No longer available 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exubera

Sponsor Name

Sponsor Name for Exubera
Sponsor Trials
Pfizer 23
Sanofi 4
Mannkind Corporation 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exubera
Sponsor Trials
Industry 30
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Boehringer Ingelheim
Moodys
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.